自身免疫性脑炎的临床试验图景:挑战与机遇
自身免疫性脑炎(AE)是神经疾病致残和致死的重要原因,治疗方案主要基于观察性研究、回顾性系列和专家意见。尽管经验性治疗有临床改善,但恢复常不完全,残留神经功能缺损和症状复发负担重,亟需更高质量循证治疗。本文综述AE过去和现在的临床试验,聚焦神经表面抗体患者,讨论罕见病临床试验的挑战与机遇并展望该领域。
要点
- AE治疗方案主要基于观察性研究、回顾性系列和专家意见,亟需更高质量循证治疗。
- AE临床试验面临招募缓慢、结局指标欠佳及不同疾病亚型包容性与排他性等挑战。
- 本文综述AE临床试验,聚焦神经表面抗体患者,讨论罕见病临床试验的挑战与机遇。
核心结论
- AE临床试验的预期知识强调需克服挑战并支持下一代临床试验的发展,但鉴于这些挑战可能需要替代方法。
研究设计与样本
- 综述:回顾过去和现在的AE临床试验,聚焦入组神经表面抗体患者的研究。
主要发现
- AE是神经疾病致残和致死的重要原因,治疗方案主要基于观察性研究、回顾性系列和专家意见。
- 尽管经验性治疗有临床改善,但恢复常不完全,残留神经功能缺损和症状复发负担重。
- AE等罕见病临床试验面临招募缓慢、结局指标欠佳及不同疾病亚型包容性与排他性等特定挑战。
局限性
- 原文未述局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autoimmune encephalitis (AE) is an important cause of neurologic morbidity and mortality. Treatment algorithms are primarily based on observational studies, retrospective series, and expert opinion. Despite clinical improvement with empiric therapy, recovery is often incomplete with a substantial burden of residual neurologic deficits and recurring symptoms. There is a pressing need for higher quality evidence-based therapies. However, designing and conducting clinical trials for patients with rare diseases such as AE has specific challenges, including slow recruitment, suboptimal outcome measures, and inclusivity vs exclusivity of the various disease subtypes. The anticipated knowledge gained from AE clinical trials emphasizes the need to overcome these challenges and support the development of the next generation of clinical trials. Yet, given these challenges, alternative approaches may be required. In this article, we review past and present clinical trials in AE with a focus on studies enrolling patients with neural surface antibodies. We discuss the potential challenges and opportunities inherent to clinical trials in rare diseases and provide an outlook for the field.
引用
- Abboud H, Clardy SL, Dubey D, et al. The Clinical Trial Landscape in Autoimmune Encephalitis: Challenges and Opportunities. Neurology. 2025. PMID: 40146951. doi:10.1212/WNL.0000000000213487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。